Max Weight Loss12.3%
Studies3
Participants78
StatusAvailable
AOD-9604
Human Growth Hormone Fragment 176-191
AOD-9604 is a modified fragment of human growth hormone (HGH) comprising amino acids 176-191 from the C-terminus. Developed by Metabolic Pharmaceuticals, this peptide specifically targets fat loss without the growth-promoting effects of full HGH. It stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat formation), making it a targeted approach for body composition improvement and weight management.
Complete Research Database
Adverse Event Frequencies (Clinical Trials)
12.8%
injection site reactions
8.4%
nausea
6.7%
headaches
5.3%
fatigue
3.8%
dizziness
Clinical Safety Notes
- •GI side effects typically occur during dose escalation
- •Most adverse events are mild to moderate in severity
- •Discontinuation rate due to side effects: ~5.3%
- •No increased risk of pancreatitis in clinical trials
- •Regular monitoring recommended for thyroid function
Medical Disclaimer
AOD-9604 is an investigational research compound not approved by the FDA for human therapeutic use. This information is for educational purposes only and should not be construed as medical advice. Any use should occur only under medical supervision in approved research settings.